Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model

Pilon-Thomas, Shari, Li, Wenbin, Briggs, Jon J., Djeu, Julie, Mule, James J. and Riker, Adam I. (2006) Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. Journal of Immunotherapy, 29 4: 381-387. doi:10.1097/01.cji.0000199199.20717.67


Author Pilon-Thomas, Shari
Li, Wenbin
Briggs, Jon J.
Djeu, Julie
Mule, James J.
Riker, Adam I.
Title Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model
Journal name Journal of Immunotherapy   Check publisher's open access policy
ISSN 1524-9557
Publication date 2006-07
Sub-type Article (original research)
DOI 10.1097/01.cji.0000199199.20717.67
Volume 29
Issue 4
Start page 381
End page 387
Total pages 7
Place of publication United States
Publisher Lippincott Williams & Wilkins
Language eng
Abstract In this study, we examined the protective and therapeutic efficacy of the immunoadjuvant CpG in combination with dendritic cell (DC) immunotherapy in a murine melanoma model. We found that murine bone-marrow derived DC stimulated in vitro with CpG displayed both enhanced expression of maturation markers and secretion of IL-12p70 and IL-10. In addition, these matured DC demonstrated enhanced ability to stimulate antigen specific CD4 and CD8 T cell responses in vitro. In a protection model, C57BL/6 mice vaccinated with either antigen-pulsed immature or CpG matured DC were unable to reject a lethal B16 melanoma challenge. In contrast, long-term protection was achieved in mice vaccinated with both CpG and antigen-pulsed DC, which correlated with an enhanced antigen specific T cell immune response. In a therapeutic model of established subcutaneous B16 melanoma, C57BL/6 mice treated intratumorally with CpG and B16 lysate-pulsed DC demonstrated a reduced tumor burden and prolonged survival. In a similar model of established subcutaneous tumor, mice treated with CpG-matured DC pulsed with a melanoma peptide, TRP-2, alone were unable to achieve tumor regression. Conversely, mice that received the combined vaccine of CpG and peptide-pulsed DC displayed a reduced tumor burden. These experiments provide evidence that combined immunization with both antigen-pulsed DC and the immunoadjuvant, CpG, can lead to tumor regression and long-term survival in a murine B16 melanoma model.
Keyword Adjuvant
CpG
Dendritic cells
Immunotherapy
Melanoma
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: ERA 2012 Admin Only
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 33 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 36 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 11 Sep 2011, 12:46:16 EST by System User on behalf of School of Medicine